Table 2.

Comparison between survivors and non-survivors with regard to clinical data and outcome parameters (N = 91).

Variables		Mortality		P-value
		Survivors (N = 72)	Non-survivors (N = 19)
Age (months), median (IQR)		7.5 (3.6–30)	10 (3–20)	0.887
Sex, n (%)
Male		39 (54.2%)	8 (42.1%)	0.349
Female		33 (45.8%)	11 (57.9%)
BMI Z score		−1.05 (−2.0–1.15)	−0.25 (2.0–1.0)	0.692
Diagnoses, n (%)
Respiratory		23 (31.9%)	6 (31.6%)	0.976
CVS		7 (9.7%)	3 (15.8%)	0.452
CNS		11 (15.3%)	3 (15.8%)	0.956
GIT & hepatic		1 (1.4%)	1 (5.3%)	0.306
Sepsis		12 (16.7%)	4 (21.1%)	0.655
Surgical		10 (13.9%)	–	0.09
Metabolic		5 (6.9%)	–	0.24
Hematological		1 (1.4%)	1 (5.3%)	0.306
Renal		2 (2.8%)	1 (5.3%)	0.589
PRISM, median (IQR)		3 (2–6)	6 (3–8)	0.039
Fasting insulin (mIU/L/), median (IQR)		5.95 (1.77–10.3)	1.9 (0.53–5)	0.030
HOMA-β %	median (IQR)	25.97 (7.05–105.66)	14.52 (6.34–22.25)	0.050
Log HOMA- β (%)	Geometric mean (95% CI)	31.37 (19.83–49.62)	12.08 (6.38–22.88)	0.048
HOMA-IR	median (IQR)	1.56 (0.64–2.43)	0.68 (0.22–2.24)	0.105
Log Homa-IR	Geometric mean (95% CI)	1.1 (0.76–1.58)	0.57 (0.28–1.16)	0.101
CRP (Positive) n (%)		33 (45.8%)	8 (42.1%)	0.771
Inotropic use, n (%)		71 (98.6%)	18 (94.7%)	0.376
PICU stay (days), median (IQR)		4 (3–6)	5 (3–10)	0.226
Hospital stay (days), median (IQR)		5.5 (4–7)	5 (4–10)	0.425
MV (days), median (IQR)	0 (0–4)		2 (1–3)	0.012

MV, mechanical ventilation; PRISM, Pediatric risk of mortality score; CVS, cardiovascular system; CNS, central nervous system; GIT, gastrointestinal tract; IQR, interquartile range.

CI, confidence interval; HOMA-IR, Homeostatic model assessment-Insulin resistance; CRP, C-reactive protein (N < 5 mg/L).

Significant values are indicated in bold.